Clinical Trial Search

Primary: SP-B Content — 19.9; 13.3 Total surfactant protein (% of PL)

Primary: Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) at Week 16 in Full Analysis Set — -0.2778; 0.0229 FEV1 liters/ eosinophils 10^9/liter — p=0.2407

Primary: Change From Baseline in the Frequency of Satisfying Sexual Events (SSE) as Recorded in the eDiary. — 1.4; 1.4; 1.9; 1.1 SSEs per 28 days

Primary: Mean Change From Baseline to 24 Weeks in the Frequency of Satisfying Sexual Events as Measured by the eDiary. — 1.5; 1.6; 1.6; 1.6 SSEs per week

Primary: Frequency of Clinical Asthma Exacerbations (CAEs) During 12 Months of Treatment — 2.115; 0.859 CAEs in 52 weeks — p=<0.0001

Primary: Satisfying Sexual Event Monthly Change From Baseline at Final Visit — 0.8; 1.4; 1.6 number of events — p=0.0454

Primary: Overall Survival Time (OS) — 11.5; 9.9 Months — p=0.0120

Primary: Absolute Change in International Cooperative Ataxia Rating Scale (ICARS) Scores From Baseline Assessment to Week 52 — 1.6; 1.7; 1.2; 1.1 units on a scale

Primary: Overall Survival Time (OS) — 11.3; 11.5 Months — p=0.9561

Primary: Frequency of Clinical Asthma Exacerbations (CAEs) During 12 Months of Treatment — 1.804; 0.904 CAEs in 52 weeks — p=<0.0001

Primary: Number of Treatment Emergent (Serious and Non-serious) Adverse Events — 100; 2; 98 number of events

Primary: Overall Survival (OS) in Participants Who Received at Least One Dose of Blinded Study Therapy at Primary Endpoint — 13.37; 12.42 months — p=0.2517

Primary: Percentage of Participants Who Died — 67.3; 69.6 percentage of participants

Primary: Overall Colon Cleansing Procedure (ITT) Measured by the Total Ottawa Scale — 8.2; 4.2 score on a scale — p=<0.0001

Primary: Number of Participants With Major Bleeding Events ［Per International Society on Thrombosis and Homeostasis (ISTH) Definition］ or Clinically Relevant Non-major (CRNM)…